Send to:

Choose Destination
See comment in PubMed Commons below
Pharmacol Biochem Behav. 2012 Feb;100(4):678-87. doi: 10.1016/j.pbb.2011.09.010. Epub 2011 Sep 25.

Novel glutamatergic agents for major depressive disorder and bipolar disorder.

Author information

  • 1LIM-27, Institute and Department of Psychiatry, University of Sao Paulo Medical School, USP, Sao Paulo, Brazil.


Mood disorders such as major depressive disorder (MDD) and bipolar disorder (BPD) are common, chronic, recurrent mental illnesses that affect the lives and functioning of millions of individuals worldwide. Growing evidence suggests that the glutamatergic system is central to the neurobiology and treatment of these disorders. Here, we review data supporting the involvement of the glutamatergic system in the pathophysiology of mood disorders as well as the efficacy of glutamatergic agents as novel therapeutics.

Published by Elsevier Inc.

[PubMed - indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science Icon for PubMed Central
    Loading ...
    Write to the Help Desk